Primary Assessment Method: Endometrial Cancer (Cohort 3)
Number of patients screened	14
Number of patients enrolled	10
Number of patients evaluable for toxicity	10
Number of patients evaluated for efficacy	6
Evaluation method	RECIST 1.1
Response assessment, CR	0 (0%)
Response assessment, PR	0 (0%)
Response assessment, SD	2 (33.3%)
Response assessment, PD	4 (66.7%)
Median duration assessments	8.9 weeks
Duration of treatment	8.9 weeks
Outcome notes	Two patients did not complete 1 cycle; of these, 1patient did not complete 1 cycle due to clinical progression and 1 patient did not complete a cycle due to intercurrent illness (a cerebrovascular accident) after 2 of 4 weekly doses in cycle 1 thought not to be related to ONC201. Two patients had clinical progression and did not have follow-up imaging.